Boehringer Ingelheim International Gmbh

Renate Konopitzky

Karl-Heinz Heider

Paul Adam

Eric Borges

Birgit Jung

Klaus-Peter Kuenkele

Pankaj Gupta

Elinborg Ostermann

Peter Seither

Priyanka Gupta

Stephen R Comeau

Andreas Zophel

Philip Nicholas Gorman

Hartmut Beug

Wolfgang Sommergruber

Sandeep Kumar

Thomas Woelfel

Horst Johann Ahorn

Andreas Wernitznig

Andreas Weith

Abdulsalam Shaaban

Norbert Kraut

Thomas Waerner

Martin Jechlinger

Ido M Tamir

Stefan Gruenert

Ulrich Koenig

Srinath Kasturirangan

David Weismann

David S Young

Taneisha Ann-Tanara Mack

The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Tri-specific binding molecules

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

CD33 binding agents

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.

Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

Tumor-associated antigens, immunogenic peptides derived therefrom and DNA molecules coding therefor, and the use thereof in the immunotherapy of cancers.

Tumor-associated antigen (R11)

Growing community of inventors

Bad Voeslau, Austria

Renate Konopitzky